- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Nephrology
Serum Aldosterone Levels Could Predict Chronic Kidney Disease Progression
August 09, 2022
An analysis of patient data from the Chronic Renal Insufficiency Cohort Study suggests increased levels of serum aldosterone were associated with an increased risk of chronic kidney disease progression.
Cardiology Month in Review: July 2022
July 30, 2022
Our cardiology month in review spotlights the most popular content from the past month. The top content from July 2022 includes hormone therapy guidance from NAMS, a look at the potential for increased risk of kidney damage with a popular statin, and a recap of upcoming decisions and trials of interest in cardiometabolic from the second half of 2022.
Don't Miss a Beat: Understanding GFR Slope, with Brendon Neuen, MBBS, MSc
July 23, 2022
In the latest edition of Don’t Miss a Beat, Drs. Greene and Vaduganathan are joined by special guest Brendon Neuen, MBBS, MSc, of the George Institute of Global Health. A trialist currently contributing to the FIND-CKD trial, Neuen takes Vaduganathan and Greene on a deep dive into the use of GFR slope as an end point in clinical trials and as a tool in clinical practice.
Dapagliflozin's Cardiorenal Benefits Consistent in T2D, Regardless of Background CV Medication Use
July 20, 2022
A secondary analysis of the DECLARE-TIMI 58 trial details the cardiorenal protective benefits of dapagliflozin across subgroups of patients defined by use of background cardiovascular medication use.
Medicare Advantage Beneficiaries Less Likely to Receive GLP-1 RA and SGLT2 Inhibitor Prescriptions
July 14, 2022
A comparison of data from more than 340,000 Medicare beneficiaries with diabetes provides insight into the real-world differences in the management of these patients, including disparities in the prescription of GLP-1 RAs and SGLT2 inhibitors.
Increased Physical Activity Linked to Lower Cardiovascular Risk in Chronic Kidney Disease
July 13, 2022
An analysis of patients with CKD from the CRIC study demonstrates those with the highest levels of physical activity had reductions in risk of 36%, 29%, and 53% for atherosclerotic events, incident heart failure, and cardiovascular mortality, respectively, compared to those with the lowest levels.
Invasive Management of Coronary Disease Less Beneficial as CKD Worsens
July 06, 2022
A recent analysis of the ISCHEMIA program suggests invasive management of chronic coronary disease appeared to provide a greater degree of benefit in those with less advanced stages of chronic kidney disease.
Invasive Approach More Beneficial than Medical Management for NSTEMI in Chronic Kidney Disease
June 24, 2022
New research from Indiana University details the impact of an invasive management strategy compared to medical management among patients with NSTEMI and chronic kidney disease across the spectrum of CKD severity.
No Red Flags for Fracture Risk with SGLT2 Inhibitors in Diabetic Kidney Disease
May 31, 2022
An analysis of data from more than 75,000 patients with diabetic kidney disease details the risk of fracture among new users of SGLT2 inhibitors compared to new users of DPP-4 inhibitors.
SGLT2 Inhibitor Prescriptions Increasing Among Cardiologists, Still Room for Improvement
April 28, 2022
An analysis of national prescription data suggests the number of prescriptions for SGLT2 inhibitors from cardiologists increased 12-fold from 2015 to 2020 while prescriptions for GLP-1 RAs increased 4-fold during the same period.